Fengzhi Medical Completes Pre-A Financing to Advance Innovative Peripheral Vascular Intervention Solutions

VCBeat has learned at the earliest opportunity that,Suzhou ForntAce Medical Technology Co., Ltd. (hereinafter referred to as “ForntAce Medical”)Recently announced the completion of its Pre-A round of financing, which was led byYuanming Xin Zhaoyuan FundExclusive investment; the financing proceeds will be used to advance the clinical development of its first product, the Sperstent® peripheral spot stent, and to support ongoing R&D for subsequent innovative pipeline candidates.Xiqiao CapitalServed as the exclusive financial advisor for this round of financing.

ForntAce Medical, established in September 2022, possesses internationally leading independent intellectual property rights and innovative technologies. Its core team has deep expertise in the field of vascular intervention, with extensive experience in the research and development of interventional implant devices, manufacturing processes, and quality control. Addressing unmet clinical needs, the company is committed to providing innovative technologies and platform-based solutions in the field of peripheral vascular intervention for patients. Its first product, the "Spot Stent," features a proprietary coating design and replaces traditional long stents as a bailout option following balloon angioplasty, achieving core advantages such as more precise implantation, simplified physician operation, and improved vessel patency.

Lower extremity arterial disease (LEAD) refers to the pathological condition of lower limb ischemia caused by arterial stenosis or occlusion due to atherosclerosis. Early symptoms typically present as intermittent claudication; if the condition continues to deteriorate, it may lead to distal ulcers, necrosis, and even the risk of forced amputation. There are approximately 45 million patients with LEAD in China. In addition to lifestyle interventions and pharmacological therapy, minimally invasive endovascular intervention has become the preferred surgical treatment. However, if the interventional outcome is suboptimal, or if a certain degree of restenosis occurs after balloon angioplasty, bailout stenting is still required as an adjunctive therapy. Based on clinical experience, approximately 30%–45% of lower extremity endovascular procedures currently require the implantation of bailout stents.

The company’s “Spot Stent,” specifically designed for lower extremity arterial lesions, addresses the design flaws of existing imported bailout stents. It offers broader indications, covering major femoropopliteal artery pathologies such as dissection, residual stenosis, and elastic recoil.The specialized coating design offers superior tissue and blood compatibility, while the product’s structural design aligns with physicians’ operational preferences and closely addresses actual clinical needs. Upholding its original commitment to “focused R&D and clinical alignment,” the company team will continue to develop innovative products that truly meet clinical demands, providing high-quality peripheral vascular interventional solutions for patients in China and around the world.

Zhou Yi, Founder of ForntAce Medicalstated: “We extend our sincere gratitude to the Yuanming Xin Zhaoyuan Fund for its support of the company’s development and for its continued confidence in the prospects of innovative technologies in the field of peripheral vascular intervention. The vascular intervention sector is a highly specialized field with significant entry barriers. We are committed not only to developing technologically advanced innovative products, but also to achieving genuine import substitution through superior manufacturing processes and quality. Minimally invasive treatment for peripheral vascular diseases remains in a phase of rapid growth, with a continuous emergence of innovative products from overseas markets. ForntAce Medical is dedicated to becoming a leader in innovative technologies for peripheral vascular intervention, thereby benefiting a broader patient population.”

Dr. Wen Yaxin, Partner at Yuanming Xin Zhaoyuan Fundstated: “We recognize the founding team’s past achievements in the field of vascular intervention and are deeply impressed by their innovation and execution capabilities. While minimally invasive treatment for peripheral vascular disease is rapidly developing in China, unmet clinical needs remain clearly defined. We are optimistic about the explosive potential of the company’s first focal stent product and its subsequent pipeline in development, and we believe that the company is capable of researching, developing, and manufacturing high-quality innovative medical devices.”

Dr. Wu Jialu, Partner at Shicui Capitalstated: “As an early investor in the company, we are impressed by the team’s execution capabilities and their efficient, pragmatic approach. The field of vascular intervention still has many unmet clinical needs, with innovative devices continuously emerging, making its market potential highly promising. We believe that a team equipped with both strong innovation capabilities and accumulated manufacturing expertise can consistently develop a high-quality and diverse product portfolio. At the same time, we extend our gratitude to the new investors for their steadfast support and look forward to working together for mutual success.”

Lu Rongchao, Partner at Xiqiao Capitalstated: “We are delighted that the company has successfully completed this round of financing. With the rapid increase in the volume of peripheral interventional procedures, we look forward to our innovative product portfolio serving more patients at an earlier date.”

Yuanming Xin Zhaoyuan Fund is an early-stage medical device angel fund under Yuanming Capital, focusing on innovative projects in the early-stage medical device sector. Its key areas of focus include cardiovascular, neurological, orthopedic, in vitro diagnostics (IVD), medical robotics, and high-end radiotherapy industries. The fund has offices in Beijing, Shanghai, Suzhou, and New York.

The team members possess extensive business experience and a proven track record in successful investments, focusing on early-stage innovative medical device projects with significant development potential and growth value. By integrating industrial resources both domestically and internationally, we deeply uncover the value of target companies and provide value-added services spanning product R&D validation, regulatory registration and clinical trials, and academic promotion. We cultivate the core competitive advantage of “Investment + Management” to build a robust industrial ecosystem and resource network.

Shicui is a mindset: independent of trends, free from bias, dedicated to quiet diligence, and committed to uncovering true value. Founded by seasoned healthcare investment professionals, Shicui Capital is dedicated to building a professional brand in early-stage healthcare investment. It empowers outstanding entrepreneurs who master emerging technologies and possess industry consolidation capabilities, driving innovation and transformation in the healthcare sector while delivering genuine investment returns.

Xiqiao Capital is an emerging boutique investment bank in China, dedicated to building a bridge between enterprises and investors with professionalism and dedication. The team members have many years of in-depth experience and abundant resources in the fields of investment banking, investment, and industry, providing diversified services in the primary market, including but not limited to corporate strategic consulting, financing and M&A, industrial integration, and cross-border services.